Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Contemporary Medical Practice

Research Progress of Sijunzi Decoction and Xiaochaihu Decoction Combined with TACE in the Treatment of Primary Liver Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXue ChenHXHaijuan Xiao

Discussion

Loading...

Member takes

Overview

Observational analysis shows Sijunzi and Xiaochaihu Decoctions enhance TACE outcomes in primary liver cancer, indicating potential immunomodulatory effects.

Key Points

  • The combined regimen improves TACE treatment efficacy and enhances patient outcomes in primary liver cancer.
  • Key metrics include reductions in ALT and AST levels, along with improved KPS scores following the treatment.
  • An analysis of clinical data indicated that cytokine production is reduced and tumor cell apoptosis is enhanced with this treatment.
  • Challenges include the need for deeper understanding of mechanisms and additional randomized controlled trials.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d64792206https://doi.org/10.53469/jcmp.2025.07(07).12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oral Chinese patent medicine combined with transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A Bayesian network meta-analysis2025
  2. 2Correction: Efficacy and safety of oral Chinese medicine combined with chemotherapy: a systematic review and network meta-analysis2025
  3. 3Beneficial effects of proprietary Chinese medicines as adjuvant therapy in patients with advanced colorectal cancer: A meta-analysis2025
  4. 4Integrating Network Pharmacology and Experimental Validation to Identifying Key Herbal Components and Targets for Liver Cancer2025
  5. 5Efficacy and Safety of PD-1 Inhibitors Combined with Transarterial Chemoembolization (TACE) and targeted Therapy in Advanced Primary Hepatocellular Carcinoma2025